Search Results - "Bergsland, Emily"

Neuroendocrine Tumors and Peptide Receptor Radionuclide Therapy: When Is the Right Time? by Hope, Thomas A, Pavel, Marianne, Bergsland, Emily K

“…Since its approval in 2018 by the US Food and Drug Administration, peptide receptor radionuclide therapy (PRRT) has become a mainstay in the treatment of…”
Get full text

Pembrolizumab for the treatment of programmed death–ligand 1‒positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE‐028 study by Mehnert, Janice M., Bergsland, Emily, O’Neil, Bert H., Santoro, Armando, Schellens, Jan H. M., Cohen, Roger B., Doi, Toshihiko, Ott, Patrick A., Pishvaian, Michael J., Puzanov, Igor, Aung, Kyaw L., Hsu, Chiun, Le Tourneau, Christophe, Hollebecque, Antoine, Élez, Elena, Tamura, Kenji, Gould, Marlena, Yang, Ping, Stein, Karen, Piha‐Paul, Sarina A.

“…Background Despite a protracted disease course and multiple available therapies, patients with well‐differentiated neuroendocrine tumors (NETs) inevitably…”
Get full text

Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors by Hope, Thomas A, Bergsland, Emily K, Bozkurt, Murat Fani, Graham, Michael, Heaney, Anthony P, Herrmann, Ken, Howe, James R, Kulke, Matthew H, Kunz, Pamela L, Mailman, Josh, May, Lawrence, Metz, David C, Millo, Corina, O'Dorisio, Sue, Reidy-Lagunes, Diane L, Soulen, Michael C, Strosberg, Jonathan R

“…Somatostatin receptor (SSTR) PET has demonstrated a significant improvement over conventional imaging (CI) in patients with neuroendocrine tumors (NETs). SSTR…”
Get full text

Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update by Baxter, Nancy N, Kennedy, Erin B, Bergsland, Emily, Berlin, Jordan, George, Thomas J, Gill, Sharlene, Gold, Philip J, Hantel, Alex, Jones, Lee, Lieu, Christopher, Mahmoud, Najjia, Morris, Arden M, Ruiz-Garcia, Erika, You, Y Nancy, Meyerhardt, Jeffrey A

“…To develop recommendations for adjuvant therapy for patients with resected stage II colon cancer. ASCO convened an Expert Panel to conduct a systematic review…”
Get full text

Optimal Timing of Surgery After Chemoradiation for Advanced Rectal Cancer: Preliminary Results of a Multicenter, Nonrandomized Phase II Prospective Trial by GARCIA-AGUILAR, Julio, SMITH, David D, AVILA, Karin, BERGSLAND, Emily K, PEIGUO CHU, KRIEG, Richard M

“…To determine whether extending the interval between chemoradiation (CRT) and surgery, and administering additional chemotherapy during the waiting period has…”
Get full text

The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors by Halfdanarson, Thorvardur R., Strosberg, Jonathan R., Tang, Laura, Bellizzi, Andrew M., Bergsland, Emily K., O'Dorisio, Thomas M., Halperin, Daniel M., Fishbein, Lauren, Eads, Jennifer, Hope, Thomas A., Singh, Simron, Salem, Riad, Metz, David C., Naraev, Boris G., Reidy-Lagunes, Diane L., Howe, James R., Pommier, Rodney F., Menda, Yusuf, Chan, Jennifer A.

“…This article is the result of the North American Neuroendocrine Tumor Society consensus conference on the medical management of pancreatic neuroendocrine…”
Get full text

Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study by Strosberg, Jonathan, Mizuno, Nobumasa, Doi, Toshihiko, Grande, Enrique, Delord, Jean-Pierre, Shapira-Frommer, Ronnie, Bergsland, Emily, Shah, Manisha, Fakih, Marwan, Takahashi, Shunji, Piha-Paul, Sarina A, O'Neil, Bert, Thomas, Sajeve, Lolkema, Martijn P, Chen, Menghui, Ibrahim, Nageatte, Norwood, Kevin, Hadoux, Julien

“…KEYNOTE-158 (ClinicalTrials.gov identifier: NCT02628067) investigated the efficacy and safety of pembrolizumab across multiple cancers. We present results from…”
Get full text

Outcomes after high-dose radiation in the management of neuroendocrine neoplasms by Chen, Katherine S, Lawhn-Heath, Courtney, Behr, Spencer, Juarez, Roxanna, Whitman, Julia, Paciorek, Alan, Nakakura, Eric K, Fidelman, Nicholas, Feng, Mary Uan-Sian, Bergsland, Emily K, Anwar, Mekhail

“…Neuroendocrine neoplasms (NENs) comprise a rare and heterogenous group of cancers, for which the role of radiation therapy continues to evolve. The purpose of…”
Get full text

The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society by Howe, James R, Cardona, Kenneth, Fraker, Douglas L, Kebebew, Electron, Untch, Brian R, Wang, Yi-Zarn, Law, Calvin H, Liu, Eric H, Kim, Michelle K, Menda, Yusuf, Morse, Brian G, Bergsland, Emily K, Strosberg, Jonathan R, Nakakura, Eric K, Pommier, Rodney F

“…Small bowel neuroendocrine tumors (SBNETs) have been increasing in frequency over the past decades, and are now the most common type of small bowel tumor…”
Get full text

Long-Term Survival Outcomes After Minimally Invasive Surgery for Ileal Neuroendocrine Tumors by Yogo, Akitada, Paciorek, Alan, Kasai, Yosuke, Moon, Farhana, Hirose, Kenzo, Corvera, Carlos U., Bergsland, Emily K., Nakakura, Eric K.

“…Background Ileal neuroendocrine tumors (i-NETs) are characterized by their multifocality and bulky mesenteric mass. Having shown that minimally invasive…”
Get full text

ASO Visual Abstract: Long-term Survival Outcomes After Minimally Invasive Surgery for Ileal Neuroendocrine Tumors by Yogo, Akitada, Paciorek, Alan, Kasai, Yosuke, Moon, Farhana, Hirose, Kenzo, Corvera, Carlos U., Bergsland, Emily K., Nakakura, Eric K.

Get full text

The Impact of Posttreatment Imaging in Peptide Receptor Radionuclide Therapy by Yadav, Surekha, Lawhn-Heath, Courtney, Paciorek, Alan, Lindsay, Sheila, Mirro, Rebecca, Bergsland, Emily K, Hope, Thomas A

“…Posttreatment imaging of γ-emissions after peptide receptor radionuclide therapy (PRRT) can be used to perform quantitative dosimetry as well as assessment…”
Get full text

The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors by Strosberg, Jonathan R, Halfdanarson, Thorvardur R, Bellizzi, Andrew M, Chan, Jennifer A, Dillon, Joseph S, Heaney, Anthony P, Kunz, Pamela L, O'Dorisio, Thomas M, Salem, Riad, Segelov, Eva, Howe, James R, Pommier, Rodney F, Brendtro, Kari, Bashir, Mohammad A, Singh, Simron, Soulen, Michael C, Tang, Laura, Zacks, Jerome S, Yao, James C, Bergsland, Emily K

“…There have been significant developments in diagnostic and therapeutic options for patients with neuroendocrine tumors (NETs). Key phase 3 studies include the…”
Get full text

Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome by Kulke, Matthew H, Hörsch, Dieter, Caplin, Martyn E, Anthony, Lowell B, Bergsland, Emily, Öberg, Kjell, Welin, Staffan, Warner, Richard R P, Lombard-Bohas, Catherine, Kunz, Pamela L, Grande, Enrique, Valle, Juan W, Fleming, Douglas, Lapuerta, Pablo, Banks, Phillip, Jackson, Shanna, Zambrowicz, Brian, Sands, Arthur T, Pavel, Marianne

“…Purpose Preliminary studies suggested that telotristat ethyl, a tryptophan hydroxylase inhibitor, reduces bowel movement (BM) frequency in patients with…”
Get full text

Combined mammalian target of rapamycin and vascular endothelial growth factor pathway inhibition in pancreatic neuroendocrine tumors: more than the sum of its parts? by Bergsland, Emily K

Get full text

Glycemic Control in Patients with Insulinoma Treated with Everolimus by Yao, James C, Bergsland, Emily K, Kulke, Matthew H

“…To the Editor: Management of refractory hypoglycemia due to malignant insulinoma is challenging. Currently available treatments include dietary modification,…”
Get full text

Withdrawal pain following patients discontinuing Trk inhibitors by Chin, Alan, Lindsay, Sheila, Bergsland, Emily K, Kang, Hyunseok

“…This article aims to expand on the existing literature regarding the incidence of withdrawal pain following discontinuation of Trk inhibitors and to explore…”
Get full text

Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer by Hege, Kristen M, Bergsland, Emily K, Fisher, George A, Nemunaitis, John J, Warren, Robert S, McArthur, James G, Lin, Andy A, Schlom, Jeffrey, June, Carl H, Sherwin, Stephen A

“…T cells engineered to express chimeric antigen receptors (CARs) have established efficacy in the treatment of B-cell malignancies, but their relevance in solid…”
Get full text

Future Directions in the Treatment of Neuroendocrine Tumors: Consensus Report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting by KULKE, Matthew H, SIU, Lillian L, VAN CUTSEM, Eric, PINGPANK, James, OBERG, Kjell, COHEN, Steven J, POSNER, Mitchell C, YAO, James C, TEPPER, Joel E, FISHER, George, JAFFE, Deborah, HALLER, Daniel G, ELLIS, Lee M, BENEDETTI, Jacqueline K, BERGSLAND, Emily K, HOBDAY, Timothy J

“…Neuroendocrine tumors (NETs) arise from a variety of anatomic sites and share the capacity for production of hormones and vasoactive peptides. Because of their…”
Get full text

Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society Guidelines for the Diagnosis and Management of Patients With Lung Neuroendocrine Tumors: An International Collaborative Endorsement and Update of the 2015 European Neuroendocrine Tumor Society Expert Consensus Guidelines by Singh, Simron, Bergsland, Emily K, Card, Cynthia M, Hope, Thomas A, Kunz, Pamela L, Laidley, David T, Lawrence, Ben, Leyden, Simone, Metz, David C, Michael, Michael, Modahl, Lucy E, Myrehaug, Sten, Padda, Sukhmani K, Pommier, Rodney F, Ramirez, Robert A, Soulen, Michael, Strosberg, Jonathan, Sung, Arthur, Thawer, Alia, Wei, Benjamin, Xu, Bin, Segelov, Eva

“…Lung neuroendocrine tumors (LNETs) are uncommon cancers, and there is a paucity of randomized evidence to guide practice. As a result, current guidelines from…”
Get more information